Vericel (VCEL) EBT (2010 - 2026)
Vericel recorded quarterly EBT of -$6.4 million in Q1 2026, down 126.4% quarter-over-quarter from $24.1 million in Q4 2025, and up 43.54% year-over-year from -$4.4 million in Q1 2025.
Vericel's EBT history runs 17 years deep, the most recent figure standing at -$6.4 million for Q1 2026.
- In Q1 2026, EBT rose 43.54% year-over-year to -$6.4 million; the TTM figure through Mar 2026 stood at $22.3 million (up 622.38% YoY), while the FY2025 annual figure was $17.4 million, up 65.34% from the prior year.
- EBT came in at -$6.4 million for Q1 2026 at Vericel, down from $24.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $24.1 million in Q4 2025 to a low of -$11.3 million in Q1 2025.
- A 5-year average of $190235.3 and a median of -$3.9 million in 2023 frame the typical range for EBT.
- On a YoY basis, EBT climbed as much as 666.04% in 2025 and fell as far as 192.81% in 2025.
- Vericel's EBT stood at $6.6 million in 2022, then surged by 112.82% to $14.1 million in 2023, then surged by 41.6% to $20.0 million in 2024, then rose by 20.96% to $24.1 million in 2025, then slumped by 126.4% to -$6.4 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$6.4 million, $24.1 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn | -6.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.37 Mn |
| Dec 31, 2025 | 24.14 Mn |
| Sep 30, 2025 | 5.10 Mn |
| Jun 30, 2025 | -529,000.00 |
| Mar 31, 2025 | -11.29 Mn |
| Dec 31, 2024 | 19.96 Mn |
| Sep 30, 2024 | -901,000.00 |
| Jun 30, 2024 | -4.67 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | 14.09 Mn |
| Sep 30, 2023 | -3.95 Mn |
| Jun 30, 2023 | -5.02 Mn |
| Mar 31, 2023 | -7.48 Mn |
| Dec 31, 2022 | 6.62 Mn |
| Sep 30, 2022 | -6.56 Mn |
| Jun 30, 2022 | -8.96 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | 4.21 Mn |
| Sep 30, 2021 | -4.93 Mn |
| Jun 30, 2021 | -3.71 Mn |
| Mar 31, 2021 | -3.15 Mn |
| Dec 31, 2020 | 12.40 Mn |
| Sep 30, 2020 | 3.62 Mn |
| Jun 30, 2020 | -8.27 Mn |
| Mar 31, 2020 | -4.71 Mn |
| Dec 31, 2019 | 9.53 Mn |
| Sep 30, 2019 | 3.48 Mn |
| Jun 30, 2019 | -19.77 Mn |
| Mar 31, 2019 | -2.88 Mn |
| Dec 31, 2018 | 7.81 Mn |
| Sep 30, 2018 | -1.49 Mn |
| Jun 30, 2018 | -4.61 Mn |
| Mar 31, 2018 | -4.75 Mn |
| Dec 31, 2017 | 1.99 Mn |
| Sep 30, 2017 | -4.35 Mn |
| Jun 30, 2017 | -2.82 Mn |
| Mar 31, 2017 | -9.88 Mn |
| Dec 31, 2016 | 1.27 Mn |
| Sep 30, 2016 | -6.47 Mn |
| Jun 30, 2016 | -4.99 Mn |
| Mar 31, 2016 | -1.99 Mn |
| Dec 31, 2015 | -4.95 Mn |
| Sep 30, 2015 | -4.87 Mn |
| Jun 30, 2015 | -2.26 Mn |
| Mar 31, 2015 | -4.56 Mn |
| Dec 31, 2014 | -2.33 Mn |
| Sep 30, 2014 | -8.02 Mn |
| Jun 30, 2014 | -8.52 Mn |
| Mar 31, 2014 | -4.64 Mn |
| Dec 31, 2013 | -4.92 Mn |
| Sep 30, 2013 | -3.64 Mn |
| Jun 30, 2013 | -5.23 Mn |
| Mar 31, 2013 | -7.16 Mn |
| Dec 31, 2012 | -7.61 Mn |
| Sep 30, 2012 | -8.28 Mn |
| Jun 30, 2012 | -9.28 Mn |
| Mar 31, 2012 | -8.56 Mn |
| Dec 31, 2011 | -7.83 Mn |
| Sep 30, 2011 | -7.43 Mn |
| Mar 31, 2011 | -6.24 Mn |
| Sep 30, 2010 | -5.83 Mn |
| Jun 30, 2010 | -5.12 Mn |